A Possible Case of Filgrastim-induced Death

Vinay P¹, Krishna S N¹, Narayana G², Jaffar S, Dixon T³

¹Pharm.D Intern, Department of Pharmacy Practice, ²Assistant Professor, ³Head of Department of Pharmacy Practice

Raghavendra Institute of Pharmaceutical Education & Research, Anantapur, Andhra Pradesh

Submitted: 21-07-2012  Accepted: 20-02-2013

INTRODUCTION

Commercially available Granulocyte-Colony Stimulating Factor (G-CSF) preparations have significantly improved the quality of life (QoL) of patients with neutropenia internationally.¹ This report summarizes the development of sore throat, breathlessness (dyspnoea), tachycardia & wheezing sound in chest associated with the use of Filgrastim which finally lead to patient's death.

CASE REPORT

A 50 year old woman was admitted in one of the private hospitals in Maharashtra, with following chief complaints;

• Diffused scaly lesions over the exterior surface of right forearm,
• Similar kind of lesions over the sun-exposed areas of face & lips &
• Black colored discoloration of skin.

On local examination, the skin of the patient was observed to be dry over the lesions with the presence of extensive scaling & patient was unable to open her mouth freely due to presence of sub-mucosal fibrosis (due to betel nuts chewing habit) over buccal region. On the basis of this data, a preliminary/provisional diagnosis was done as exposure dermatitis & drug hypersensitivity. The past medical & medication history of patient were asthma since 18 years & the patient was on unknown anti-asthmatic medications. There was no past medical history of cancer. Clinical laboratory tests (hematological tests) were carried out, which revealed that there was a gradual decrease in the neutrophil count (21.2%) & total count (500cells/mm³) & increase in the Erythrocyte Sedimentation Rate (98mm/hr). On the basis of these clinical laboratory values a final diagnosis was then made as Drug-induced neutropenia. Identification of drug/s which induced neutropenia was not done. A 300 mcg prefilled syringe of Filgrastim was administered subcutaneously once daily, for 4 days to treat drug-induced neutropenia. Other drugs like ceftriaxone, amikacin, liquid paraffin lotion, and chlorhexidine mouthwash were also given to treat lesions & sub-mucosal fibrosis respectively.

On very next day (day 2) of the treatment, patient complained of having sore throat, throat pain & fever. On day 3, she developed breathlessness (dyspnoea), tachycardia & drowsiness along with continuing sore throat & throat pain. On examining lungs, wheezing sounds from the chest were heard. On day 4, patient's daughter reported patient's restlessness which on observation was found to be severe seizure attacks with froth coming out of her mouth followed by cardiac arrest. On examination, she was found to be unconscious, her pulse was not palpating, pupils were not dilated & not reacting to light, no heartbeats & no breathing sounds were heard. Cardio-Pulmonary Resuscitation (CPR) was tried on the patient by starting chest compressions with ambu-bag (at the rate of 30:2 breaths) to save her life. CPR was given for around 20-25 minutes (6 times). Along with CPR, Intravenous (IV) bolus injections of atropine – 1mg/ml (10 ampoules) & adrenaline – 1mg/ml (2 ampoules) were also administered. In spite of all the above rescue methods according to Advanced Cardiac/Cardiovascular Life Support (ACLS) protocols,³ the patient could not survive and was medically declared dead.
**DISCUSSION**

In this case, *drug-induced neutropenia* was diagnosed & treated on the basis of clinical laboratory investigations other than Absolute Neutrophil Count (ANC) which is a main key for diagnosing neutropenia.

Furthermore the patient was treated with Filgrastim without identifying the drug/s that caused neutropenia. Filgrastim is considered to be a drug of choice in neutropenic cases. But in this case, development of sore throat, breathlessness (dyspnoea), tachycardia & wheezing sound in chest might have been triggered due to filgrastim, as sore throat was observed as an adverse drug reaction (ADR) or an undesirable effect in some of the randomized clinical trials conducted on Filgrastim & the other effects (dyspnoea, tachycardia & wheeze) are given under the “WARNING” column of Filgrastim as serious allergic reactions. Secondly, as the patient had a past medical history of asthma, more care should have been taken in prescribing filgrastim to the patient because of the possibility of these systemic allergic-like reactions. In one of a randomized, open-labelled, multi-centric study, patients with severe allergic history (seasonal/recurrent asthma) were excluded from their study due to the above reasons. Taking all this information into consideration, a causality assessment of death was done by using Naranjo’s Causality Assessment Algorithm which indicated filgrastim as a possible cause of death with Naranjo score = 3.

**CONCLUSION**

This case report accentuates the importance of collecting complete data of patient's history such as; past medical history, past medication history, current clinical laboratory tests, etc. before initiating any treatment. Also monitoring, reporting & management of ADRs are necessary in order to avoid such types of severe events.

**ACKNOWLEDGEMENTS**

I would like to give thanks to my colleagues & my professors for guiding me in assessing the causal relationships of drugs & their effects. I would like to declare that there is no conflict of interest of any of the authors of this article.

**REFERENCES**